Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Axogen Inc (AXGN)

Axogen Inc (AXGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 286,156
  • Shares Outstanding, K 43,688
  • Annual Sales, $ 159,010 K
  • Annual Income, $ -21,720 K
  • 60-Month Beta 1.03
  • Price/Sales 1.91
  • Price/Cash Flow N/A
  • Price/Book 3.15
Trade AXGN with:

Options Overview Details

View History
  • Implied Volatility 160.22% ( +13.58%)
  • Historical Volatility 39.55%
  • IV Percentile 98%
  • IV Rank 96.45%
  • IV High 166.04% on 10/18/23
  • IV Low 1.83% on 11/09/23
  • Put/Call Vol Ratio 6.00
  • Today's Volume 21
  • Volume Avg (30-Day) 18
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 1,620
  • Open Int (30-Day) 1,524

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.25
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.30 +3.17%
on 04/19/24
8.25 -21.21%
on 04/04/24
-1.18 (-15.36%)
since 03/19/24
3-Month
6.30 +3.17%
on 04/19/24
10.83 -39.99%
on 02/27/24
-2.28 (-25.97%)
since 01/19/24
52-Week
3.45 +88.41%
on 11/01/23
10.83 -39.99%
on 02/27/24
-3.60 (-35.64%)
since 04/19/23

Most Recent Stories

More News
AxoGen: Q4 Earnings Snapshot

AxoGen: Q4 Earnings Snapshot

AXGN : 6.50 (-0.76%)
AxoGen: Q3 Earnings Snapshot

AxoGen: Q3 Earnings Snapshot

AXGN : 6.50 (-0.76%)
AxoGen: Q2 Earnings Snapshot

AxoGen: Q2 Earnings Snapshot

AXGN : 6.50 (-0.76%)
AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 33.33% and 2.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AXGN : 6.50 (-0.76%)
HYPR : 0.8300 (+2.47%)
AxoGen: Q1 Earnings Snapshot

AxoGen: Q1 Earnings Snapshot

AXGN : 6.50 (-0.76%)
OrthoPediatrics (KIDS) Reports Q1 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 7%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

KIDS : 30.31 (+2.89%)
AXGN : 6.50 (-0.76%)
AxoGen: Q4 Earnings Snapshot

AxoGen: Q4 Earnings Snapshot

AXGN : 6.50 (-0.76%)
ViewRay Announces Preliminary Fourth Quarter and Full Year 2022 Results; appoints William P. "Bill" Burke as Chief Financial Officer

/PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended...

MIRO : 3.39 (+0.59%)
AXGN : 6.50 (-0.76%)
VRAY : 0.0250 (-39.90%)
Here's Why "Trend" Investors Would Love Betting on AxoGen (AXGN)

If you are looking for stocks that are well positioned to maintain their recent uptrend, AxoGen (AXGN) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength"...

AXGN : 6.50 (-0.76%)
AxoGen (AXGN) Reports Q3 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 93.33% and 2.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AXGN : 6.50 (-0.76%)
SGHT : 5.13 (-2.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

AxoGen, Inc. engages in developing and marketing surgical solutions for peripheral nerves. The company's portfolio of products includes Avance Nerve Graft(R), AxoGuard Nerve Connector(R), AxoGuard Nerve Protector(R), Avive Soft Tissue Membrane(R), AcroVal Neurosensory & Motor Testing System(R) and AxoTouch...

See More

Key Turning Points

3rd Resistance Point 6.93
2nd Resistance Point 6.77
1st Resistance Point 6.63
Last Price 6.50
1st Support Level 6.33
2nd Support Level 6.17
3rd Support Level 6.03

See More

52-Week High 10.83
Fibonacci 61.8% 8.01
Fibonacci 50% 7.14
Last Price 6.50
Fibonacci 38.2% 6.27
52-Week Low 3.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar